AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35340949 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nalbuphine (group N)
Number of subjects: 66
Study 35340949 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg fentanyl (group F)
Number of subjects: 66
Study 35340949 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (group C)
Number of subjects: 66
Study 32172198 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 2000 mg/day
Number of subjects: 219
Study 32172198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 34749724 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical exposure of impacted canines with dissected dental follicle (DF) stitching to muscle and mucosa
Number of subjects: 24
Study 34749724 — intervention group
Group type: COMPARATOR
Intervention: Contralateral unimpacted canines
Number of subjects: 24
Study 32594478 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Behavior Therapy (IBT, n=51)
Number of subjects: 101
Study 32594478 — intervention group
Group type: COMPARATOR
Intervention: e-mail education (EE, n=50)
Number of subjects: 101
Study 34996788 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based intervention including educational outreach visit, computerized decision tool, and self-management application for patients.
Number of subjects: 36
Study 34996788 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based intervention
Number of subjects: 36
Study 33691451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node metastasis (LNM) nomogram
Number of subjects: 22403
Study 33691451 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant metastasis nomogram
Number of subjects: 22403
Study 33023684 — intervention group
Group type: EXPERIMENTAL
Intervention: IVB nitroglycerin (NTG)
Number of subjects: 44
Study 35685573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/day for eight weeks)
Number of subjects: 60
Study 35685573 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard treatment for analgesia (oral diclofenac 75 mg/12 h as needed)
Number of subjects: 60
Study 34770611 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent visual feedback
Number of subjects: 19
Study 34770611 — intervention group
Group type: COMPARATOR
Intervention: Terminal visual feedback
Number of subjects: 19
Study 34770611 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of concurrent feedback
Number of subjects: 19
Study 34770611 — intervention group
Group type: COMPARATOR
Intervention: Concurrent vs Terminal feedback
Number of subjects: 19
Study 34701886 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT+CCRT
Number of subjects: 97
Study 34701886 — intervention group
Group type: COMPARATOR
Intervention: CCRT
Number of subjects: 97
Study 32255395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 43
Study 32255395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 34114223 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation and music intervention
Number of subjects: 62
Study 32833475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training (CBMT) intervention delivered via an 8-session, at-home, electronic tablet.
Number of subjects: 0
Study 32833475 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 32833475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training (CBMT) intervention
Number of subjects: 0
Study 34664109 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg CBD, 5.4 mg THC, and 6.6 mg CBC daily
Number of subjects: 43
Study 34664109 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg CBD, 10.8 mg THC, and 13.2 mg CBC daily
Number of subjects: 43
Study 34664109 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg CBD, 16.2 mg THC, and 19.8 mg CBC daily
Number of subjects: 43
Study 34664109 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg CBD, 21.6 mg THC, and 26.4 mg CBC daily
Number of subjects: 43
Study 34664109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 34664109 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of CBD, THC, and CBC
Number of subjects: 43
Study 35730901 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral movement-based computer games + conventional rehabilitation
Number of subjects: 93
Study 35730901 — intervention group
Group type: COMPARATOR
Intervention: Video-directed exercise + conventional rehabilitation (control group)
Number of subjects: 93
Study 32600393 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-2 receptor antagonist (H2RA)
Number of subjects: 100
Study 32600393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35369704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve-guided PCI
Number of subjects: 1500
Study 35369704 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1500
Study 34798895 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor Ailment Service (MAS)
Number of subjects: 808
Study 34798895 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 808
Study 33299898 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPT)
Number of subjects: 80
Study 33299898 — intervention group
Group type: COMPARATOR
Intervention: Second IVIG treatment
Number of subjects: 80
Study 36194219 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-sparing protocol (naproxen, acetaminophen, pantoprazole, limited hydromorphone, educational infographic)
Number of subjects: 200
Study 36194219 — intervention group
Group type: COMPARATOR
Intervention: Standard care (opioid analgesic)
Number of subjects: 200
Study 36194219 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study 36194219 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-sparing protocol
Number of subjects: 200
Study 33472391 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT Grief-Help
Number of subjects: 134
Study 33472391 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling
Number of subjects: 134
Study 32702101 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg per day) for 4 weeks followed by 10 weeks of meloxicam
Number of subjects: 364
Study 32702101 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by CBT for 10 weeks
Number of subjects: 364
Study 32702101 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by CBT
Number of subjects: 364
Study 35318752 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant with immediate provisional restoration and socket preservation
Number of subjects: 50
Study 35318752 — intervention group
Group type: COMPARATOR
Intervention: Early implant placement with guided bone regeneration and delayed loading
Number of subjects: 50
Study 32324435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously on days 1 and 15, surgery planned on day 29.
Number of subjects: 39
Study 35822829 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) intervention involving structured conversations led by skilled nurses after a two-day training session.
Number of subjects: 0
Study 35822829 — intervention group
Group type: EXPERIMENTAL
Intervention: Information brochure provided to participants as part of the intervention.
Number of subjects: 0
Study 32315342 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential new-born care practices
Number of subjects: 417
Study 32315342 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe cord care practice
Number of subjects: 417
Study 32315342 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal thermal care practices
Number of subjects: 417
Study 32315342 — intervention group
Group type: EXPERIMENTAL
Intervention: Good neonatal feeding practices
Number of subjects: 417
Study 32315342 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal Care (ANC) visits
Number of subjects: 417
Study 32315342 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of essential new-born care
Number of subjects: 417
Study 32315342 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselled about essential new-born care
Number of subjects: 417
Study 35695753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 2-chloroprocaine 40 mg in Group 1
Number of subjects: 120
Study 35695753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 2-chloroprocaine 35 mg in Group 2
Number of subjects: 120
Study 35695753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 2-chloroprocaine 45 mg in Group 3
Number of subjects: 120
Study 35695753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 2-chloroprocaine (varied doses based on CRM)
Number of subjects: 120
Study 33714527 — intervention group
Group type: EXPERIMENTAL
Intervention: oAPBI (once daily)
Number of subjects: 113
Study 33714527 — intervention group
Group type: COMPARATOR
Intervention: tAPBI (twice daily)
Number of subjects: 113
Study 32741071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.025 mg/kg
Number of subjects: 210
Study 32741071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.050 mg/kg
Number of subjects: 210
Study 32741071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.075 mg/kg
Number of subjects: 210
Study 32741071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.100 mg/kg
Number of subjects: 210
Study 32741071 — intervention group
Group type: COMPARATOR
Intervention: Sham group (normal saline)
Number of subjects: 210
Study 35092948 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU tablet)
Number of subjects: 109
Study 35092948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 34794426 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized depression risk score
Number of subjects: 40
Study 34867829 — intervention group
Group type: EXPERIMENTAL
Intervention: Liothyronine (LT3)
Number of subjects: 59
Study 34867829 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine (LT4)
Number of subjects: 59
Study 34867829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LT3 and LT4
Number of subjects: 59
Study 32005971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) insertion before the last quadrant emulsification (Group III, n=130)
Number of subjects: 401
Study 32005971 — intervention group
Group type: COMPARATOR
Intervention: Standard setting (Group I, n=134)
Number of subjects: 401
Study 32005971 — intervention group
Group type: COMPARATOR
Intervention: Reduced vacuum and flow rate (Group II, n=137)
Number of subjects: 401
Study 34651505 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training with feedback (FB)
Number of subjects: 48
Study 34651505 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training with taping (TP)
Number of subjects: 48
Study 34651505 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular team schedule)
Number of subjects: 48
Study 33737331 — intervention group
Group type: EXPERIMENTAL
Intervention: Visitor guidelines allowing parental visitation restricted to 1 parent
Number of subjects: 239
Study 33737331 — intervention group
Group type: COMPARATOR
Intervention: Visitor guidelines not changed since initial review
Number of subjects: 239
Study 34971795 — intervention group
Group type: EXPERIMENTAL
Intervention: Health‐4‐Families intervention (16-week distance-based intervention)
Number of subjects: 206
Study 32112181 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Clomiphene Citrate
Number of subjects: 124
Study 32112181 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Clomiphene Citrate
Number of subjects: 124
Study 36883163 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing the puzzle game
Number of subjects: 44
Study 36883163 — intervention group
Group type: COMPARATOR
Intervention: Watching (control group)
Number of subjects: 44
Study 33637409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet computer game (n = 30)
Number of subjects: 60
Study 33637409 — intervention group
Group type: COMPARATOR
Intervention: Standard departmental preparation (n = 30)
Number of subjects: 60
Study 32304015 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib (dose range 20-450 mg, once daily)
Number of subjects: 0
Study 32304015 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib coadministered with itraconazole (CYP3A4 inhibitor)
Number of subjects: 0
Study 32304015 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib coadministered with rifampicin (CYP3A inducer)
Number of subjects: 0
Study 32304015 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib coadministered with midazolam (CYP3A4 substrate)
Number of subjects: 0
Study 32304015 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib coadministered with cephalexin (multidrug and toxin extrusion 1 substrate)
Number of subjects: 0
Study 32304015 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib in subjects with hepatic impairment
Number of subjects: 0
Study 36307315 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicines (IHMs)
Number of subjects: 60
Study 36307315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34649534 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Counselling (IPC)
Number of subjects: 52
Study 34649534 — intervention group
Group type: COMPARATOR
Intervention: perinatal specific cognitive behavioural therapy (CBT)
Number of subjects: 52
Study 32443364 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program using smart wearable device for 6 weeks
Number of subjects: 40
Study 32443364 — intervention group
Group type: COMPARATOR
Intervention: Self-exercise program as normal for 6 weeks
Number of subjects: 40
Study 36177651 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D diagnosed <50 years
Number of subjects: 25141
Study 36177651 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D
Number of subjects: 25141
Study 34660501 — intervention group
Group type: EXPERIMENTAL
Intervention: Free oral HIV self-test kits (HIVST) offered to participants
Number of subjects: 305
Study 34660501 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 305
Study 34660501 — intervention group
Group type: EXPERIMENTAL
Intervention: Free oral HIV self-test kits (HIVST)
Number of subjects: 305
Study 32195955 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 0
Study 32195955 — intervention group
Group type: COMPARATOR
Intervention: Simple facemask
Number of subjects: 0
Study 35817957 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (425 mg/d for 2 years, then 850 mg/d for 2 years)
Number of subjects: 30
Study 35817957 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 30
Study 35817957 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 30
Study 34029880 — intervention group
Group type: EXPERIMENTAL
Intervention: Online psychosocial intervention adjunctive to an activity monitor (Fitbit)
Number of subjects: 0
Study 35395953 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized and home-based speech therapy for 8 weeks
Number of subjects: 215
Study 35395953 — intervention group
Group type: COMPARATOR
Intervention: No intervention (waiting list control)
Number of subjects: 215
Study 33522977 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic internet-based protocol (TIBP)
Number of subjects: 216
Study 33522977 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic internet-based protocol with positive affect component (TIBP+PA)
Number of subjects: 216
Study 33522977 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL) control group
Number of subjects: 216
Study 32333541 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (Jingjin needling)
Number of subjects: 80
Study 32333541 — intervention group
Group type: COMPARATOR
Intervention: Medication (Prednisone acetate, Acyclovir, Vitamin B12, Vitamin B1)
Number of subjects: 80
Study 35435470 — intervention group
Group type: EXPERIMENTAL
Intervention: Knotless PEEK anchors
Number of subjects: 78
Study 35435470 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable anchors
Number of subjects: 78
Study 34028112 — intervention group
Group type: EXPERIMENTAL
Intervention: TightRail™ mechanical rotating dilator sheath
Number of subjects: 372
Study 34028112 — intervention group
Group type: COMPARATOR
Intervention: Excimer laser sheaths
Number of subjects: 372
Study 34028112 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 372
Study 32776425 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched unrelated donor bone marrow transplantation (MUD BMT)
Number of subjects: 23
Study 32776425 — intervention group
Group type: COMPARATOR
Intervention: Immune suppression therapy (IST)
Number of subjects: 23
Study 36306548 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-coaching (TC)
Number of subjects: 14
Study 36306548 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 14
Study 33634446 — intervention group
Group type: EXPERIMENTAL
Intervention: Restarted anticoagulation within 14 days
Number of subjects: 352
Study 33634446 — intervention group
Group type: EXPERIMENTAL
Intervention: Restarted anticoagulation
Number of subjects: 352
Study 33634446 — intervention group
Group type: COMPARATOR
Intervention: Not restarted anticoagulation
Number of subjects: 352
Study 34883037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored therapy (TT)
Number of subjects: 282
Study 34883037 — intervention group
Group type: COMPARATOR
Intervention: PAM-B therapy
Number of subjects: 282
Study 34700258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy to Prevent Suicide (MBCT-S)
Number of subjects: 135
Study 34700258 — intervention group
Group type: COMPARATOR
Intervention: enhanced treatment as usual (eTAU)
Number of subjects: 135
Study 36216700 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCA with selective FFRCT
Number of subjects: 1399
Study 36216700 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical pathways
Number of subjects: 1399
Study 34000949 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type-A (BTX-A) infiltration (100 UI)
Number of subjects: 16
Study 34000949 — intervention group
Group type: COMPARATOR
Intervention: Physiologic serum infiltration (placebo)
Number of subjects: 16
Study 32912276 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 300
Study 34877858 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.3% amphotericin B in 30% dimethyl sulfoxide cream
Number of subjects: 20
Study 34877858 — intervention group
Group type: COMPARATOR
Intervention: 30% dimethyl sulfoxide cream (vehicle cream)
Number of subjects: 20
Study 33504338 — intervention group
Group type: EXPERIMENTAL
Intervention: Mis-implementation of chronic disease programs
Number of subjects: 0
Study 33504338 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational factors influencing mis-implementation
Number of subjects: 0
Study 34270689 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 g of intrusive force per segment (40 g per root)
Number of subjects: 20
Study 34270689 — intervention group
Group type: COMPARATOR
Intervention: 200 g of intrusive force per segment (20 g per root)
Number of subjects: 20
Study 32734413 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video on LARC methods (7-minute duration)
Number of subjects: 270
Study 32734413 — intervention group
Group type: COMPARATOR
Intervention: Non-video group (control)
Number of subjects: 270
Study 35134185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine as postexposure prophylaxis
Number of subjects: 689
Study 35134185 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 2 suspected index cases
Number of subjects: 689
Study 35134185 — intervention group
Group type: COMPARATOR
Intervention: County incidence
Number of subjects: 689
Study 33227361 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted genetic risk score (wGRS)
Number of subjects: 1938
Study 33227361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ln-transformed Matsuda index
Number of subjects: 1938
Study 33227361 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA2-IR
Number of subjects: 1938
Study 33164956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic core-postural chain stabilization (DCS) exercises
Number of subjects: 31
Study 33164956 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental treatment (NDT) exercises
Number of subjects: 31
Study 37286262 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic-guided HF management
Number of subjects: 1000
Study 37286262 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1000
Study 36106642 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCoV-19)
Number of subjects: 32450
Study 36106642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32450
Study 32533875 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared oral care intervention
Number of subjects: 41
Study 36150974 — intervention group
Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 606
Study 36150974 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 606
Study 32949780 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz repetitive TMS (rTMS) synchronized to the positive peak of the sensorimotor μ-oscillation
Number of subjects: 0
Study 32949780 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz repetitive TMS (rTMS) synchronized to the negative peak of the sensorimotor μ-oscillation
Number of subjects: 0
Study 32949780 — intervention group
Group type: COMPARATOR
Intervention: 1 Hz repetitive TMS (rTMS) at random phase (control)
Number of subjects: 0
Study 36285573 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard bolus
Number of subjects: 25
Study 36285573 — intervention group
Group type: COMPARATOR
Intervention: Split bolus 60/40 with 20% increment
Number of subjects: 25
Study 36285573 — intervention group
Group type: COMPARATOR
Intervention: Split bolus 50/50 with 20% increment
Number of subjects: 25
Study 36285573 — intervention group
Group type: COMPARATOR
Intervention: Split bolus 50/50
Number of subjects: 25
Study 36285573 — intervention group
Group type: COMPARATOR
Intervention: Split bolus 70/30
Number of subjects: 25